PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.70
-0.07 (-1.21%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close5.77
Open5.77
Bid5.55 x 4000
Ask5.98 x 3100
Day's range5.65 - 5.99
52-week range5.01 - 9.42
Volume1,656,099
Avg. volume1,830,467
Market cap481.892M
Beta (3Y Monthly)2.80
PE ratio (TTM)N/A
EPS (TTM)-0.65
Earnings date31 Oct 2018 - 5 Nov 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.50
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Recent Analysis Shows Progenics Pharmaceuticals, Catabasis Pharmaceuticals, Warrior Met Coal, Preformed Line Products, Express, and Sanmina Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire9 days ago

    Progenics Advances 1095, PSMA-Targeted Therapeutic Candidate for the Treatment of Metastatic Prostate Cancer, into Phase 2 Clinical Development Following Discussions with the FDA

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced plans to advance I-131 1095, its PSMA-targeted therapeutic, into a Phase 2 clinical study. The multicenter, randomized, controlled trial will evaluate the efficacy and safety of 1095 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who are PSMA-avid, chemotherapy naïve, and progressed on abiraterone.

  • GlobeNewswire12 days ago

    Progenics Announces Publication of Pivotal Trial of AZEDRA® (iobenguane I 131) in The Journal of Nuclear Medicine

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that the Company’s pivotal trial of AZEDRA® (iobenguane I 131), the Company’s radiotherapeutic, has been published in The Journal of Nuclear Medicine. The study entitled, “Efficacy and Safety of High-Specific-Activity I-131 MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma,” reports the complete results of the pivotal study of AZEDRA. This trial was the largest multicenter, prospective trial to evaluate the safety and efficacy of any therapy in patients with pheochromocytoma and paraganglioma and formed the basis of AZEDRA’s approval by the U.S. Food and Drug Administration (FDA) in July 2018.

  • Generic-Drugs Stock Outlook: No Respite from Pricing Issues
    Zacks12 days ago

    Generic-Drugs Stock Outlook: No Respite from Pricing Issues

    Generic-Drugs Stock Outlook: No Respite from Pricing Issues

  • GlobeNewswire16 days ago

    Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer

    -PyL highly sensitive, 93-99%, in reliably detecting metastatic prostate cancer lesions and highly specific, 96-99%, in confirming the absence of pelvic lymph node disease-.

  • Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
    Market Realist24 days ago

    Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

    In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).

  • GlobeNewswire26 days ago

    Progenics Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference in New York City on Tuesday, October 2, 2018 at 11:30 a.m. Eastern Daylight Time.

  • Progenics Pharma's Stock Down on Dismal Phase III Study Data
    Zackslast month

    Progenics Pharma's Stock Down on Dismal Phase III Study Data

    Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection.

  • GlobeNewswirelast month

    Progenics Announces Addition of AZEDRA® (iobenguane I 131) to National Comprehensive Cancer Network Guidelines for Pheochromocytoma and Paraganglioma

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that AZEDRA® (iobenguane I 131), the Company’s radiotherapeutic, has been added to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors v 3.2018. NCCN Guidelines® are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors. NCCN Guidelines have been updated with AZEDRA, the first and only FDA approved treatment of patients 12 and older with iobenguane scan positive, locally unresectable and metastatic pheochromocytoma or paraganglioma.

  • Associated Presslast month

    Qualcomm and Tailored Brands rise; Kroger stumbles

    Stocks that moved substantially or traded heavily Thursday: Progenics Pharmaceuticals Inc., down $1.30 to $6 The company reported disappointing results from a study of an imaging compound used in prostate ...

  • Here's Why Shares of Progenics Pharmaceuticals Inc. Sank Today
    Motley Foollast month

    Here's Why Shares of Progenics Pharmaceuticals Inc. Sank Today

    A phase 3 trial failed, but all isn't lost for the biotech.

  • After-hours buzz: PVTL, PGNX & more
    CNBClast month

    After-hours buzz: PVTL, PGNX & more

    See which stocks are posting big moves after the bell on Wednesday.

  • GlobeNewswirelast month

    Progenics Pharmaceuticals Reports Top Line Phase 3 Data for Prostate Cancer Imaging Agent 1404

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced top line data from its Phase 3 study of 1404, the Company’s prostate specific membrane antigen (PSMA)-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer. The Phase 3 trial evaluated the specificity of 1404 imaging to identify patients without clinically significant prostate cancer and sensitivity to identify patients with clinically significant disease.

  • Amicus Therapeutics: Recent Developments, Financial Overview
    Market Realistlast month

    Amicus Therapeutics: Recent Developments, Financial Overview

    In August, the FDA approved Amicus Therapeutics’ (FOLD) Galafold for the treatment of adults with a confirmed diagnosis of Fabry disease along with an amenable galactosidase alpha gene variant. The FDA’s approval of Galafold was according to the accelerated approval process based on the decrease in KIC GL-3 (kidney interstitial capillary cell globotriaosylceramide) substrate. Studies estimate that more than 3,000 individuals in the United States have Fabry disease.

  • How Analysts View Amicus Therapeutics in September
    Market Realistlast month

    How Analysts View Amicus Therapeutics in September

    On September 10, Amicus Therapeutics (FOLD) announced the regulatory and clinical progress of its AT-GAA development program for Pompe disease. The company has met with the FDA to discuss the regulatory trajectory for AT-GAA, and the FDA has provided final written minutes of the meeting. Amicus Therapeutics has implemented the suggestions of the FDA and the European Medicines Agency for the study.

  • Analysts Are Bullish on Verastem in September
    Market Realistlast month

    Analysts Are Bullish on Verastem in September

    On September 11, Verastem (VSTM) stock closed at $9.17, which is ~13% below its 52-week high of $10.35 on September 4. On September 6, Verastem announced that the company completed dosing the first patient with duvelisib and venetoclax combination therapy for the multicenter phase 1/2 trial at the Dana-Farber Cancer Center. Verastem is evaluating the safety and efficacy of duvelisib and venetoclax combination therapy for the treatment of individuals with relapsed or refractory chronic lymphoblastic leukemia or small lymphocytic lymphoma.

  • Why Invitae Stock Rose 23% in Week Ended August 24
    Market Realist2 months ago

    Why Invitae Stock Rose 23% in Week Ended August 24

    On August 24, Invitae (NVTA) stock closed at $12.56, which represents a ~4.75% growth from its prior day’s close of $11.99. It hit its 52-week high of $12.75 on August 24. For the week ended August 24, Invitae stock closed at $12.56, which represents a ~23% rise from its prior week’s close of $10.21 on August 17. Invitae delivered solid growth in the second quarter of 2018 when it reported revenues of $37.3 million compared to $14.3 million in Q2 2017.

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on The Michaels Companies, Glu Mobile, Natus Medical, Progenics Pharmaceuticals, QuinStreet, and Jaguar Health — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...

  • What Does Nektar Therapeutics’ Valuation Trend Indicate?
    Market Realist2 months ago

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY). 

  • Analysts Remain Bullish on Nektar Stock in August
    Market Realist2 months ago

    Analysts Remain Bullish on Nektar Stock in August

    Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.

  • Opko Health: Q2 Expenditures, Developments, Recommendations
    Market Realist2 months ago

    Opko Health: Q2 Expenditures, Developments, Recommendations

    In August, Opko Health completed the enrollment of its worldwide Phase 3 trial of somatrogon in children with GHD (growth hormone deficiency). In July, Health Canada approved Rayaldee, a product of Opko Health and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP), for commercialization in the Canadian market for the treatment of individuals with secondary hyperthyroidism who are at stage 3 or stage 4 of chronic kidney disease and have vitamin D insufficiency. In July, Opko Health announced the completion of its enrollment of 110 candidates for the initiation of its Phase 2b dose escalation clinical study of OPK88003, an injectable oxyntomodulin drug with GLP-1 and glucagon dual agonist activity for the treatment of individuals with Type 2 diabetes and obesity.

  • How Opko Health Fared in the Second Quarter of 2018
    Market Realist2 months ago

    How Opko Health Fared in the Second Quarter of 2018

    In the second quarter, Opko Health reported a net loss of $6.2 million compared to a net loss of $16.9 million in Q2 2017. In the first half of 2018, it reported a net loss of $49.3 million compared to a net loss of $51.4 million in the first half of 2017. In the second quarter, it reported a diluted loss per share of $0.01 compared to a loss of $0.04 in Q2 2017. In the first half of 2018, it reported a diluted net loss per share of $0.09 compared to a diluted net loss per share of $0.11 in the first half of 2017.

  • GlobeNewswire2 months ago

    Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    The gross proceeds from the sale of the primary shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $75 million. The offering is expected to close on or about August 10, 2018, subject to customary closing conditions. Progenics also granted the underwriters a 30-day option to purchase 1,363,636 additional shares of common stock on the same terms and conditions as the shares offered in the public offering.

  • GlobeNewswire2 months ago

    Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Progenics Pharmaceuticals, Inc. (PGNX) announced today that it is offering to sell shares of its common stock in an underwritten public offering pursuant to an effective shelf registration statement. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual terms of the offering. Jefferies and Credit Suisse are acting as joint book-running managers for the proposed offering.

  • Associated Press3 months ago

    Progenics: 2Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 20 cents. The biopharmaceutical company posted revenue of $3.9 million in the period. Progenics shares have risen 34 percent since ...